This is a summary of a presentation by Prof. Barry Laird, MD which you can find here. Before participating, please read our CME and disclosure information which can be found here.

This activity is supported by an independent medical educational grant from Pfizer. This online education program has been designed for for US Healthcare Professionals only.

Cancer Cachexia: Key Clinical Summary

Cancer cachexia is highly prevalent but routinely identified far too late, often only after severe weight loss and functional decline. Recognizing cachexia earlier—before progressive, irreversible muscle loss occurs—creates a crucial window where multimodal interventions can still alter the patient's trajectory and preserve their tolerance to systemic anticancer therapy. Cachexia affects up to 80% of patients with advanced cancer and contributes to 20–30% of cancer-related deaths.

Diagnostic Criteria at a Glance

According to the Fearon et al. international consensus, cancer cachexia is diagnosed if a patient meets any one of the following three alternative criteria (these are not a checklist):

• Unintentional weight loss >5% over the past 6 months, in the absence of simple starvation.
• BMI <20 kg/m² plus ongoing weight loss >2%.
• Sarcopenia plus ongoing weight loss >2%.

A patient may have clinically significant cancer cachexia despite having a normal BMI and a preserved performance status. For example, an unintentional body weight loss of 6.1% over 3 months in a patient with a normal BMI of 24.3 kg/m² definitively establishes the diagnosis.

Think Trajectory, Not Today's Weight

A single weight measurement in isolation reveals nothing about the patient's metabolic trajectory. A normal BMI does not exclude cancer cachexia. Always establish:

• Current weight and previous weight (specifically over the past 6 months).
• Percentage of unintentional weight loss.
• Current BMI.
• The BMI-adjusted weight-loss grade.

Interpreting the degree of weight loss in the context of the patient's BMI provides a highly predictive indicator of survival and condition severity.

Cachexia is a Trajectory, Not a Terminal Event

Cachexia exists on a continuum, and identifying it early opens a window for effective management:

• Pre-cachexia: Weight loss ≤5%, accompanied by anorexia and early metabolic changes.
• Cachexia: Meets consensus criteria, or exhibits reduced intake with systemic inflammation, but remains responsive to multimodal intervention.
• Refractory cachexia: Characterized by advanced catabolism, low performance status, and a life expectancy of less than 3 months, where management is solely symptom-directed.

Not All Weight Loss is Cachexia

Cancer cachexia cannot be fully reversed by conventional nutritional support alone. These conditions frequently overlap, and secondary sarcopenia driven by disease and inflammation can occur as part of cancer cachexia.

Feature	Cancer Cachexia	Primary Age-Related Sarcopenia	Malnutrition / Reduced Intake	Treatment-Related Weight Loss
Predominant Driver	Tumor-driven metabolic change plus reduced intake	Low muscle mass/strength from aging, inactivity, or disease	Insufficient intake, absorption, or mechanical barrier	Nausea, mucositis, taste change, diarrhea, fatigue
Systemic Inflammation	Typically present (↑ CRP, ↓ albumin)	Variable, often absent	Absent unless a secondary process coexists	Variable, often treatment-timed
Response to Nutrition Alone	Cannot be fully reversed	Partial, with resistance exercise	Reversible once intake is restored	Usually reversible once symptoms are controlled
Bedside Clues	Loss continues despite adequate intake; early satiety	Low muscle mass with a stable weight	Identifiable intake barrier	Loss tracks with the treatment cycle

When Screening is Abnormal: Assess

SCREEN → ASSESS → DOCUMENT → ACT/REFER

Once an abnormality is detected, perform a structured clinical assessment covering these five domains:

• Nutritional intake: Compare usual portions to current intake, note days of reduced intake, and use validated screening tools (e.g., MUST, PG-SGA SF).
• Nutrition-impact symptoms: Identify treatable barriers like early satiety, taste changes, nausea, constipation, and pain.
• Muscle mass and physical function: Utilize L3 skeletal muscle index from existing staging CTs, mid-arm circumference, or hand-grip strength. Assess ECOG performance status, gait speed, or timed up-and-go tests.
• Systemic inflammation: Check CRP and albumin levels, or calculate the Modified Glasgow Prognostic Score to distinguish cachexia from simple undernutrition.

Document So Recognition Leads to Action

An unwritten diagnosis cannot trigger a multidisciplinary response. Ensure the patient's record captures:

• Percentage weight loss and the specific timeframe.
• Current BMI and BMI-adjusted weight-loss grade.
• A formal diagnosis of cachexia and its clinical stage.
• Relevant nutritional, functional, and inflammatory findings.
• The multidisciplinary referral plan and scheduled reassessment.

From Recognition to Action

Recognizing weight loss must immediately change the management plan. Action means completing a structured assessment and initiating multidisciplinary interventions. It does not mean simply documenting the weight and waiting, advising the patient to solely eat more calories, or deferring intervention until performance status irreversibly declines.

Three Actions for Your Next Clinic

• 1. Ask for the 6-month weight. Today's number in isolation tells you nothing. Establish previous weight to calculate the percentage of weight loss and reveal the trajectory.
• 2. Don't let a normal BMI reassure you. Clinically important cachexia can be present in patients within normal or overweight BMI ranges. Grade the weight loss against the BMI.
• 3. Name it – and document the stage. Documenting "cachexia" in the problem list is the necessary trigger for assessment, referral, and follow-up care.

Recognition only matters if it changes the plan.

References

1. Fearon K, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncology. 2011;12(5):489-495.
2. Martin L, et al. Diagnostic criteria for the classification of cancer-associated weight loss. Journal of Clinical Oncology. 2015;33(1):90-99.
3. Muscaritoli M, et al. ESPEN practical guideline: clinical nutrition in cancer. Clinical Nutrition. 2021;40(5):2898-2913.
4. Arends J, et al. Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines. ESMO Open. 2021;6(3):100092.

Content is accurate as of the date of release.